Reviewing resTORbio Inc. (TORC)’s and Affimed N.V. (NASDAQ:AFMD)’s results

Both resTORbio Inc. (NASDAQ:TORC) and Affimed N.V. (NASDAQ:AFMD) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
resTORbio Inc. N/A 0.00 54.91M -2.06 0.00
Affimed N.V. N/A 0.00 N/A -0.70 0.00

In table 1 we can see resTORbio Inc. and Affimed N.V.’s gross revenue, earnings per share (EPS) and valuation.


Table 2 hightlights the return on assets, return on equity and net margins of the two companies.

Net Margins Return on Equity Return on Assets
resTORbio Inc. 0.00% -67.6% -50.1%
Affimed N.V. 0.00% -82.1% -63.5%


resTORbio Inc. has a Current Ratio of 14.5 and a Quick Ratio of 14.5. Competitively, Affimed N.V.’s Current Ratio is 3.7 and has 3.6 Quick Ratio. resTORbio Inc.’s better ability to pay short and long-term obligations than Affimed N.V.

Analyst Recommendations

The Ratings and Recommendations for resTORbio Inc. and Affimed N.V. are featured in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
resTORbio Inc. 0 0 0 0.00
Affimed N.V. 0 0 2 3.00

Affimed N.V. on the other hand boasts of a $4.5 average target price and a 31.58% potential upside.

Insider & Institutional Ownership

resTORbio Inc. and Affimed N.V. has shares held by institutional investors as follows: 43.4% and 42.9%. resTORbio Inc.’s share held by insiders are 55.61%. Competitively, 16.7% are Affimed N.V.’s share held by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
resTORbio Inc. -3.52% 5.79% 2.61% 24.26% 0% -25.36%
Affimed N.V. -20.09% -9.6% -25.42% 70.48% 88.42% 175.38%

For the past year resTORbio Inc. has -25.36% weaker performance while Affimed N.V. has 175.38% stronger performance.


On 4 of the 7 factors Affimed N.V. beats resTORbio Inc.

resTORbio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. Its lead program is targeting the selective inhibition of TORC1, an evolutionary conserved pathway that contributes to the decline in function of multiple organ systems, including the immune, cardiac, and neurologic systems. The company's lead drug candidate RTB101 is a selective, orally administered, TORC1 inhibitor, which is being tested in a Phase 2b clinical trial as a first in-class immunotherapy for reducing the incidence of respiratory tract infections in the elderly by enhancing the function of the immune system. It also intends to develop RTB101 for additional aging-related indications, such as heart failure or neurodegenerative diseases. The company was founded in 2016 and is based in Boston, Massachusetts.

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in Germany and internationally. Its lead candidate is AFM13, a natural killer cell (NK-cell) TandAb designed for the treatment of CD30-positive (CD30+) B- and T-cell malignancies, including Hodgkin lymphoma. The companyÂ’s product candidates include AFM24, a NK-cell that treats epidermal growth factor receptor expressing solid tumors, such as lung, head, neck, and colon cancers; AFM26, which binds to B-cell maturation antigen (BCMA) for the treatment of multiple myeloma; and Trispecific Abs for the treatment of multiple myeloma. Its product candidates also comprise AFM11, a T-cell TandAb, which is in Phase I clinical trial for the treatment of various CD19+ B-cell malignancies, including non-Hodgkin Lymphoma and acute lymphocytic leukemia; and AMV564, a CD33/CD3-specific T-cell TandAb for the treatment of acute myeloid leukemia and other hematologic malignancies. The company has license agreements with Amphivena Therapeutics, Inc., Deutsches Krebsforschungszentrum, and Xoma Ireland Limited; research funding agreement with The Leukemia & Lymphoma Society; and collaboration with Merck Sharp & Dohme B.V. It also has a clinical development and commercialization collaboration with The University of Texas MD Anderson Cancer Center to evaluate AFM13 in combination with MD AndersonÂ’s NK-cell product. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.